, /PRNewswire/ -- Medtronic plc (NYSE: ), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes Association's (ADA) 84 Scientific Sessions that showcases the benefits of the MiniMedTM 780G system. New data shows how the system addresses hyperglycemia and nighttime burden, adding to the established body of evidence that demonstrates the system's ability to tackle unique and burdensome challenges of diabetes, such as managing highs and meal-time management or carb counting, while also mirroring outcomes across a wide-ranging patient population. Among the burdens of living with diabetes, hyperglycemia can often be overshadowed by hypoglycemia.
Yet, in the U.S., only 26% of people living with diabetes achieve HbA1c levels of 20 mg/dL from compared to 12 – at least 30% of the nights.
The transition from the MiniMedTM 770G system to the MiniMedTM 780G system decreased dawn phenomenon rates from 12.2% to 4.5%.
Time in Range also increased from 87.7% to 91.4% from 12 – , which is consistent with dawn phenomenon trends.
Early and consistent management of hyperglycemia is critical as it has protective effects on the body that can last for decades. "For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one's control," explained Robert Vigersky, MD, Chief Medical Officer, Medtronic Diabetes. "The introduction of the MiniMedTM 780G system has made it easier to maintain target g.
